BioAge Labs (US.BIOA)
Capital Allocation Audit · Period: 2022 – 2026
Key Metrics
US.BIOA · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.8% | → |
| ROE | -12.9% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.01 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.BIOA (BioAge Labs) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.8% → ROE -12.9% ↓ Cash Conversion - → D/E Ratio 0.01 ↑ Gross Margin 0.0% ↓
Key Metrics
US.BIOA (BioAge Labs) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.8% →ROE -12.9% ↓Cash Conversion - →D/E Ratio 0.01 ↑Gross Margin 0.0% ↓Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies